Board summary
Key figures
61,014
Registered population
61.4% aged 18–64
15.8%
Aged 65+
ICB 18.8% · England 17.9%
16.9%
Ethnic minority (non-White)
8.2% Asian · England 9.6%
2.8%
In IMD quintile 1
ICB 0.8% · England 21.0%
~1,631
Core20 residents (est.)
Resident basis; registered basis ~1,695 · see page 3
6,222
Hypertension register
+6.32% in 3 yrs · England +5.60%
470
SMI register
40.8% of Reigate and Banstead's
637
COPD register
Reviews -20.12% in 3 yrs
Forecast to 2030
7,477
Hypertension patients, 2030
+1,255 on today
62.6%
QRISK ≥20% on statins, 2030
+1.37pp over 3 yrs
4.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
COPD annual review completion fell over 2023–2025.
COPD annual reviews fell 20.1% over 2023 to 2025 to 68.6% (England +2.8%, 76.4%) while register prevalence grew +8.3%, which may reflect recall pressure.
Vaccination and Core20 gaps sit in one practice.
QOF vaccination achievement spans 56.8 pp from 27.2% at The House Partnership (Core20 4.4%) to 84.0% at The Wall House Surgery (Core20 0.0%).
Hypertension blood pressure control exceeds comparator benchmarks.
Blood pressure control reaches 73.7% (England 70.3%), though recorded prevalence is 12.1% (England 15.2%), which may reflect a younger list (15.8% aged 65+).
Population, age and ethnicity
A younger list with 22.8% aged 0-17 contrasts with 1,329 catchment care beds
The PCN registers 61,014 patients across The House Partnership (38,701) and The Wall House Surgery (22,313). Those aged 0-17 comprise 22.8%, above Reigate and Banstead (21.0%), the ICB (20.4%) and England (19.6%), while 15.8% are aged 65+ (borough 19.4%, ICB 18.8%, England 17.9%). Area Census residents are 83.1% White (borough 84.4%, ICB 85.3%, England 81.1%) and 8.2% Asian (borough 7.5%, ICB 7.7%, England 9.6%), describing local residents rather than registered patients. Projected list growth to 2030 is +4.8% (borough +3.2%, ICB +4.9%, England +2.3%), based on an unverified methodology.
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Reigate and Banstead local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Reigate and Banstead LA) | 2,154 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.7% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.9% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Reigate and Banstead LA) | 991 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Reigate and Banstead LA) | 8.9 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 2.8% PCN-wide and concentrated entirely at The House Partnership
The PCN records an average IMD decile of 7.6 (Reigate and Banstead 8.0, ICB 7.9, England 5.5). Its Core20 share of 2.8% is below England (21.0%) but above Reigate and Banstead (1.1%) and the ICB (0.8%). Deprivation sits entirely at The House Partnership (4.4% Core20 share, an estimated 1,695 patients), whereas The Wall House Surgery has 0.0%. Resident estimates show 1,631 people in one decile-2 LSOA, though practice and resident counts use different bases. Core20 outreach is therefore best directed to The House Partnership.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
470
SMI register
0.92% recorded prevalence
298
Learning disability register
0.58% recorded prevalence
48
Care homes, 1,329 beds
In the PCN catchment
7.9%
Provide unpaid care
Reigate and Banstead, Census 2021
Recorded prevalence is 0.9% for severe mental illness (470 patients) and 0.6% for learning disability (298 patients), representing 40.8% and 36.8% of borough registers. Catchment areas include 48 care homes (1,329 beds). Borough rough sleeping (6 in 2025) does not describe registered lists.
Severe mental illness: physical health checks
Over three years, SMI physical checks fell: BMI recording dropped 8.2 pp to 79.6% (England +5.1 pp) and blood pressure checks fell 3.7 pp to 82.0% (England +4.4 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,222
Hypertension register
+6.32%
Register growth, 3 yrs
Reigate and Banstead +4.55% · England +5.60%
+2.87pp
BP control, under 80
≤140/90 · +2.45pp aged 80+
+1,255
More patients by 2030
Forecast 7,477 (13.70%)
Hypertension case-finding and control
Recorded hypertension prevalence is 12.1% (6,222 patients), below Reigate and Banstead (14.0%), NHS Surrey Heartlands ICB (14.3%) and England (15.2%), consistent with a younger list (15.8% aged 65+ vs England 17.9%). Blood pressure control is strong overall: 73.7% are treated to target (England 70.3%), and under-80 control is 70.9% (England 67.8%). However, achievement is uneven: at The House Partnership, 66.7% are treated to target and 63.8% of under-80s achieve control, versus 82.5% and 80.4% at The Wall House Surgery. Blood pressure control falls below England at The House Partnership, so focused blood pressure review and recall at that practice should be prioritised.
Lipids and statins
Among patients with QRISK ≥ 20%, 59.7% receive lipid-lowering therapy (England 63.6%, NHS Surrey Heartlands Integrated Care Board 59.4%). Primary-prevention statin coverage in diabetes fell 3.3% over three years to 69.5% (England 73.2%, +2.1%). Fewer at-risk patients are on lipid-lowering therapy than England, suggesting scope for primary-prevention recall.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 52,579 | £2.10 | £2.24 | £1.86 | £110,416 |
| Cardiovascular (all), 2025 | 74,106 | £4.28 | £4.74 | £3.33 | £317,174 |
In 2026, the PCN prescribed 52,579 lipid-regulating drug items at £2.10 per item (England £1.86, NHS Surrey Heartlands ICB £2.24), spending £12,619 more than at England's unit cost but £7,361 less than at NHS Surrey Heartlands Integrated Care Board's unit cost. Higher unit costs than England indicate an opportunity to review lipid-regulating formulary choices without restricting indicated treatment.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+1.24%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−4.08%
Asthma prevalence, PCN 3-yr % change
The COPD register grew +8.3% over three years to 637 patients (England +2.6%), but annual review completion fell 20.1% to 68.6% (England +2.8%), reaching 60.5% at The House Partnership and 83.8% at The Wall House Surgery. Asthma prevalence fell 4.1% over three years to 6.3% (England +0.5%) across 3,018 patients; a 65.6% review rate leaves an estimated 1,037 patients without an annual review. Prescribing for ages 5-19 is 829 items per 1,000 (England 1,488).
Cancer register and children's immunisation
The cancer register records 1,963 patients (3.8%, England 3.8%). In Q1 2025/26 child health, 12-month 6-in-1 coverage is 88.0%, below the 95% target by 7 pp, while 24-month coverage is 96.5%. At age 5, MMR first-dose coverage is 97.3% and second-dose coverage is 93.2%, a 4.1 pp difference between doses in the same cohort.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
In 2022, NHS Surrey Heartlands ICB diagnosed 61.4% of cancers with a known stage at stage 1 or 2 (England 55.3%), below the 75.0% national ambition by 2028, requiring about 650 extra early-stage cases annually across the ICB. Known-stage completeness was 67.7% (England 67.0%). These ICB figures reflect system context rather than PCN performance. Locally, PCN cervical screening coverage in women aged 25 to 49 is 69.7% after falling 3.3% over 2023 to 2025 (England -1.0%), dropping to 64.0% at The House Partnership, while breast screening reached 70.2% (+10.0% over 2023 to 2024; England +8.4%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Surrey and Sussex Healthcare NHS Trust achieved 77.7% on the 28-day faster diagnosis standard against the 75.0% standard (Croydon Health Services NHS Trust 83.2%, Epsom and St Helier University Hospitals NHS Trust 89.7%, NHS Surrey and Sussex Integrated Care Board 79.3%, England 79.3%). Its 62-day referral to treatment performance was 70.0% against the 85.0% standard (Croydon Health Services NHS Trust 69.9%, Epsom and St Helier University Hospitals NHS Trust 86.8%, NHS Surrey and Sussex Integrated Care Board 71.5%, England 71.2%). Across all diagnostic tests, 28.5% of patients waited 6+ weeks (England calculated: 23.1%).
| Pathways within standard (%) | Surrey and Sussex Healthcare | Epsom and St Helier | Croydon Health | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.74 | 89.70 | 83.22 | 79.29 | 79.32 |
| 31-day treatment (96%) | 96.20 | 99.16 | 99.06 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 69.97 | 86.82 | 69.88 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Surrey and Sussex Healthcare | Epsom and St Helier | Croydon Health | England |
|---|---|---|---|---|
| MRI | 27.53 | 0.31 | 0.26 | 21.40 |
| CT | 18.49 | 1.06 | 7.69 | 9.92 |
| Echocardiography | 43.78 | 25.49 | 3.60 | 28.48 |
| Colonoscopy | 15.11 | 33.01 | 21.80 | 30.83 |
| Gastroscopy | 21.06 | 30.90 | 17.94 | 29.02 |
| All 15 DM01 tests | 28.50 | 6.83 | 3.51 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In June 2026, Surrey residents recorded 109,530 provisional community care contacts across 33,510 patients, with 69.6% of contacts involving adults aged 65+. Across NHS Surrey and Sussex Integrated Care Board, 85,660 patients had 309,615 contacts and 47,125 patients received 66,930 referrals. These experimental figures reflect broad county and system activity rather than PCN caseloads.
Practice variation and patient experience
Vaccination achievement spans 56.8 pp between practices, alongside divergent patient satisfaction scores
Both practices achieved 100.0% in the 2025/26 QOF clinical domain (England 97.1%). Overall achievement reached 91.7% at The House Partnership and 98.2% at The Wall House Surgery. However, vaccination and immunisation achievement diverged by 56.8 pp, from 27.2% at The House Partnership (England 55.2%) to 84.0% at The Wall House Surgery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Wall House | 116 | 0.0 | 62.0% | 71.6% | 83.9% |
| House Partnership | 107 | 4.4 | 70.3% | 62.5% | 74.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
COPD reviews fell 20.1% over three years while blood pressure control reached 70.9%
Over three years, the PCN's widest delivery lags appear in annual reviews. COPD reviews fell 20.1% (England +2.8%), while severe mental illness BMI recording fell 8.2 pp (England +5.1 pp) and alcohol recording fell 7.1 pp (England +5.4 pp). Non-frail diabetes control fell 2.1% (England +4.4%) to 56.9%. Conversely, hypertension blood pressure control under 80 rose 4.2% (England +3.2%) to 70.9% (England 67.8%), and heart failure reviews reached 88.6% (England 78.5%). Prioritising recall for respiratory, diabetes, and mental health registers could reverse these delivery slides.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD reviews
BMI record (SMI)
Alcohol record (psychosis)
BP check (SMI)
Diabetes HbA1c control
Breast screening (53-70)
BP control, under 80
BP control, 80+
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Reigate and Banstead | Asset | PCN | Reigate and Banstead |
|---|---|---|---|---|---|
| Care homes (catchment) | 48 (1,329 beds) | n/a | Schools (catchment) | 69 | n/a |
| Children's centres | 5 | 8 | Places of worship | 64 | 70 |
| Libraries | 5 | 6 | Food banks (VCS) | 6 | 6 |
| Homelessness support (VCS) | 1 | 2 | Day centres (VCS) | 23 | 40 |
| Children and young people (VCS) | 7 | 8 | Carers support groups (VCS) | 6 | 6 |
| Primary schools (LA maintained) | 11 | 14 | Primary academies | 16 | 18 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Targeted Core20 and vaccination outreach
QOF vaccination achievement spans 56.8 pp (27.2% at The House Partnership vs 84.0% at The Wall House Surgery; England 55.2%), and all 1,695 estimated Core20 patients (4.4%) sit at The House Partnership. For discussion: concentrate proactive immunisation catch-up, call-recall review and flexible clinic slots at The House Partnership. Moderate effort to run.
Evidence base: the share of patients in the most deprived quintile is the Core20 targeting measure used to weight inequalities funding, outreach and prevention capacity, and the gradient every clinical indicator should be read against.
Policy anchor: Core20PLUS5 (Core20 = the most deprived 20% by IMD); 10 Year Health Plan, with widening inequalities the equity test of reform.
Option 2
Respiratory annual review recall reset
COPD reviews fell 20.1% over 2023 to 2025 to 68.6% across 637 patients (England 76.4%, +2.8%; The House Partnership 60.5% vs The Wall House Surgery 83.8%), and 65.6% asthma review coverage across 3,018 patients leaves about 1,000 unreviewed. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
SMI physical health check consolidation
Across 470 SMI patients (0.9%, 40.8% of the borough register), 2023 to 2025 recording fell for BMI (8.2 pp to 79.6%, England +5.1 pp), alcohol (7.1 pp to 79.4%, England +5.4 pp) and BP (3.7 pp to 82.0%, England +4.4 pp). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric demand capacity planning (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall audit (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension control recall audit (p5) | Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | Practice |
| Infant immunisation recall review (p6) | 6-in-1 coverage at 12 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Appointment booking workflow review (p9) | GPPS last request led to a booked appointment | 10YHP, hospital to community | Practice |
| Option 1 · Targeted Core20 and vaccination outreach (p12) | Core20 cohort (IMD quintile 1) · QOF vaccination and immunisation-domain achievement | Core20PLUS5 · 10YHP equity test | PCN & Practice |
| Option 2 · Respiratory annual review recall reset (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 respiratory | PCN & Practice |
| Option 3 · SMI physical health check consolidation (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
